Ample Room Available for Novel Products in Metastatic Prostate Cancer Treatment Market
Despite numerous product launches in the metastatic castration-resistant prostate cancer (mCRPC) treatment market since 2010, ample opportunity still exists for drug developers to claim their stake in the arena, particularly through drugs with novel molecular targets, says an analyst with research and consulting firm GlobalData.
Raksha Mudbhary, PhD, GlobalData's Analyst covering oncology and hematology, states that while mCRPC remains an incurable disease, its treatment landscape has been revolutionised by the approval of five new drugs in recent years.
Mudbhary says: “Chemotherapy docetaxel was the standard of care in the mCRPC therapeutics market prior to 2010. Since then, second-generation hormonal therapies, such as Johnson and Johnson’s Zytiga and Astellas/Medivation’s more recently launched Xtandi, have established themselves as the dominant players.
“Both drugs were initially approved for patients who progress following treatment with docetaxel, but they have since also shown an Overall Survival (OS) benefit in chemotherapy-naïve patients, allowing them to challenge docetaxel’s position as the gold-standard, first-line mCRPC treatment.”
However, GlobalData has found that the majority of patients receiving Zytiga or Xtandi encounter disease progression within one year of treatment, and cross-resistance between the two drugs is increasingly being recognized. Plenty of room is therefore available for new and more effective products, although these will have to demonstrate an OS benefit to gain regulatory approval.
Mudbhary continues: “This is where notable Phase III failures have occurred in the past year, involving drugs developed by the likes of Takeda and Oncogenex. San Francisco-based Exelixis announced earlier this month that its investigational drug, Cometriq, had also failed to show an improvement in OS, compared with prednisone in a Phase III trial.
“While these failures highlight the difficulty in treating this advanced stage of prostate cancer, drug developers should not be deterred from entering a therapeutics market with so much opportunity.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance